Mesoblast (NASDAQ:MESO) has earned a consensus recommendation of “Hold” from the nine ratings firms that are currently covering the firm, MarketBeat reports. Three analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $13.92.
Several research firms have recently weighed in on MESO. Maxim Group set a $14.00 target price on shares of Mesoblast and gave the stock a “buy” rating in a research report on Thursday. Credit Suisse Group downgraded shares of Mesoblast from a “neutral” rating to an “underperform” rating and set a $6.00 target price for the company. in a research report on Thursday, March 22nd. Cantor Fitzgerald set a $23.00 target price on shares of Mesoblast and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Zacks Investment Research downgraded shares of Mesoblast from a “buy” rating to a “hold” rating in a research report on Tuesday, January 23rd. Finally, Oppenheimer set a $16.00 target price on shares of Mesoblast and gave the stock a “buy” rating in a research report on Wednesday, December 20th.
A hedge fund recently bought a new stake in Mesoblast stock. Princeton Capital Management LLC acquired a new stake in shares of Mesoblast (NASDAQ:MESO) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 124,022 shares of the company’s stock, valued at approximately $724,000. Princeton Capital Management LLC owned about 0.13% of Mesoblast as of its most recent SEC filing. Institutional investors and hedge funds own 2.85% of the company’s stock.
Mesoblast (NASDAQ:MESO) last released its earnings results on Tuesday, February 27th. The company reported ($0.10) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.09. The company had revenue of $13.40 million during the quarter, compared to the consensus estimate of $0.34 million. Mesoblast had a negative net margin of 188.83% and a negative return on equity of 9.78%. sell-side analysts expect that Mesoblast will post -0.49 earnings per share for the current year.
Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions.
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.